Stocks · News reference
Anavex Life Sciences Reports Preliminary Q2 Net Loss Of $0.06 Per Share vs. $0.13 A Year Ago; $127.4M Cash Funds Operations Into Mid-To-Late Fiscal 2028
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 30, 2026, 12:06 PM
- Checked
- Jul 30, 2026, 12:06 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — ANAVEX LIFE SCIENCES CORP. (AVXL)
Filed: 2026-08-25 AccNo: 0001731122-26-001143 Size: 295 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarAnavex Life Sciences Q3 EPS $0.08 Beats $(0.08) Estimate
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.08) by 200 percent. This is a 150 percent increase over losses of $(0.16) per share from
Read original at benzingaAnavex Life Sciences Urges Stockholders To Reject Attempt By PVG Asset Management And Patrick S. Adams To Acquire Control Of The Company
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life SciencesMr. Patel and Dr. Senderowicz to Stand for Election at 2026 Annual Meeting with
Read original at benzinga